Frequently Asked Questions
The market is segmented based on , By Source Type (Bacterial Diseases, Virusal Diseases, Fungal Disease, and Parasitic Disease), Disease Type (Jaundice, Leprosy, Listeria, Lyme Disease, Malaria, Measles, Molluscum Contagiosum , Norovirus, Pyelonephritis, Rabies, Severe Acute Respiratory Syndrome, Sepsis, Tetanus, West Nile, Zika, Ebola Disease, and Others), Treatment Type (Medication, Dietary Supplements, and Surgery), Mode of Action Type (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, and Antiparasitic Drugs), Drug Type (Tafenoquine, Omadacycline, Tecovirimat, Eravacycline, Delafloxacin, Plazomicin, Benznidazole, Secnidazole, Daclatasvir, Dalbavancin, and Others), Route of Administration (Oral, Topical, and Intravenous), End-Users (Hospitals, Homecare, Specialty Clinics,and Others) – Industry Trends and Forecast to 2031.
.
The Global Infectious Disease Drug Market size was valued at USD 80.51 USD Billion in 2023.
The Global Infectious Disease Drug Market is projected to grow at a CAGR of 5.45% during the forecast period of 2024 to 2031.
The major players operating in the market include F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), ViiV Healthcare group of companies (U.K.), Sanofi S.A (France), Eli Lilly and Company (U.S.), Novartis AG (Switzerland), Mitsubishi Tanabe Pharma Corporation (Japan).
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East and Africa.
